Stifel Financial Corp Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Stifel Financial Corp lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,830 shares of the biopharmaceutical company’s stock after selling 109 shares during the quarter. Stifel Financial Corp’s holdings in Alnylam Pharmaceuticals were worth $1,603,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. TD Asset Management Inc boosted its holdings in shares of Alnylam Pharmaceuticals by 6.0% in the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after acquiring an additional 27,592 shares during the period. Charles Schwab Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after purchasing an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares during the period. Swiss National Bank grew its position in Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after purchasing an additional 63,385 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $245.44 on Friday. The stock has a market capitalization of $31.66 billion, a price-to-earnings ratio of -93.68 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company’s 50-day simple moving average is $264.61 and its 200-day simple moving average is $250.74. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The firm’s revenue was down 33.3% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ALNY shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 over the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.